Article
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
International journal of cancer - 1 May 2006
Gronwald Jacek, Tung Nadine, Foulkes William D, Offit Kenneth, Gershoni Ruth, Daly Mary, Kim-Sing Charmaine, Olsson Hakan, Ainsworth Peter, Eisen Andrea, Saal Howard, Friedman Eitan, Olopade Olufunmilayo, Osborne Michael, Weitzel Jeffrey, Lynch Henry, Ghadirian Parviz, Lubinski Jan, Sun Ping, Narod Steven A
Abstract excerpt
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is approximately 30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.